Literature DB >> 25533529

Effects of single N-glycosylation site knockout on folding and defibrinogenating activities of acutobin recombinants from HEK293T.

Inn-Ho Tsai1, Ying-Ming Wang2, Kai-Fa Huang2.   

Abstract

Acutobin, the α-fibrinogenase from Deinagkistrodon acutus venom, contains four N-glycosylation sites with disialylated complex-typed glycans. Here, we explore the functional roles of each of the N-glycan by site-directed mutagenesis. The wild-type (ATB-wt) and single glycan-knockout mutants of recombinant acutobin were prepared from HEK293T, demonstrating that mutations at Asn(77), Asn(81) and Asn(100) impaired the folding while the S79A mutant and various Asn(229)-deglycosylated mutants were correctly folded. Based on homology modeling of acutobin and multiple sequence alignment with various venom thrombin-like enzymes, the importance of a hydrophilic environment at each glycosylation site to the enzyme folding could be rationalized. Remarkably, all the mutants showed similar catalytic activities for the chromogenic substrate and similar thermal stabilities as ATB-wt, suggesting that the glycan knockout did not affect the gross conformation and stability of the active sites. Although SDS-PAGE analyses revealed that ATB-wt and the D229-mutant degraded all human fibrinogen subunits faster but less specifically in vitro as compared with other mutants that cleaved only the α-subunit, ATB-wt and D229-mutant were not able to release fibrinogen-peptide A and thus coagulated human plasma slower than the other mutants did. In the mice model, the defibrinogenating effect of ATB-wt was stronger and lasting-longer than those of all the mutants. Taken together, all the glycans contribute to the pharmacokinetics of acutobin and ATB-wt in vivo, and the microenvironment around the Asn(229)-glycan appears to regulate the fibrinogen-chain specificity of acutobin while the N-glycans at positions 77, 81 and 100 are crucial for its folding.
Copyright © 2014 Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  Anticoagulant agent; Fibrinogenase chain specificity; HEK 293T recombinant; Mutagenesis of N-Glycosylation sites; Snake venom thrombin-like enzyme

Mesh:

Substances:

Year:  2014        PMID: 25533529     DOI: 10.1016/j.toxicon.2014.12.008

Source DB:  PubMed          Journal:  Toxicon        ISSN: 0041-0101            Impact factor:   3.033


  3 in total

1.  Mutation of N-linked glycosylation at Asn548 in CD133 decreases its ability to promote hepatoma cell growth.

Authors:  Ying Liu; Shifang Ren; Liqi Xie; Chunhong Cui; Yang Xing; Chanjuan Liu; Benjin Cao; Fan Yang; Yinan Li; Xiaoning Chen; Yuanyan Wei; Haojie Lu; Jianhai Jiang
Journal:  Oncotarget       Date:  2015-08-21

2.  Glycoengineering of EphA4 Fc leads to a unique, long-acting and broad spectrum, Eph receptor therapeutic antagonist.

Authors:  Cassandra L Pegg; Leanne T Cooper; Jing Zhao; Michael Gerometta; Fiona M Smith; Michael Yeh; Perry F Bartlett; Jeffrey J Gorman; Andrew W Boyd
Journal:  Sci Rep       Date:  2017-07-26       Impact factor: 4.379

3.  GP73 N-glycosylation at Asn144 reduces hepatocellular carcinoma cell motility and invasiveness.

Authors:  Kai Jiang; Wei Li; Qinle Zhang; Guoquan Yan; Kun Guo; Shu Zhang; Yinkun Liu
Journal:  Oncotarget       Date:  2016-04-26
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.